NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pat…
Medical - Diagnostics & Research
US, Fort Myers [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -15.99 | -223.91 | 266.52 | |
| Graham Fair Price | 35.91 | 5.95 | 4.37 | |
| PEG | -85.21 | -0.20 | 1.33 | |
| Price/Book | -2.88 | 2.10 | 2.16 | |
| Price/Cash Flow | -67.56 | -61.61 | 189.94 | |
| Prices/Earnings | 49.57 | -17.93 | -35.56 | |
| Price/Sales | -5.16 | 12.42 | 13.10 | |
| Price/FCF | -67.56 | -61.61 | 189.94 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -8.65 | 0.40 | 0.43 | |
| Operating Margin | -50.99 | -0.18 | -0.12 | |
| ROA | -93.60 | -0.02 | < 0.005 | |
| ROE | -0.02 | -0.03 | -92.60 | |
| ROIC | -0.01 | -0.02 | -67.51 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | < 0.005 | -42.11 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.23 | -0.52 | 122.36 | |
| EPS QOQ | 0.27 | -0.91 | 240.91 | |
| FCF QOQ | 2.10 | -3.94 | 87.65 | |
| Revenue QOQ | 0.02 | < 0.005 | -81.32 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 24.72 | 19.41 | -21.47 | |
| Days Sales Outstanding (DSO) | 75.93 | 81.86 | 7.82 | |
| Inventory Turnover | 3.64 | 4.64 | 27.34 | |
| Debt/Capitalization | 0.39 | 0.37 | -5.93 | |
| Quick Ratio | 5.67 | 6.87 | 21.07 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 7.48 | 7.32 | -2.07 | |
| Cash | 3.30 | 3.05 | -7.45 | |
| Capex | -0.06 | -0.04 | 20.97 | |
| Free Cash Flow | 0.09 | -0.25 | 193.23 | |
| Revenue | 1.24 | 1.24 | 0.30 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad